Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273391 | 1.00 | LPL (0.40) | LPLLIPGLTA4HCXCR2SLC6A4 | |
| SCHEMBL14630064 | 0.83 | LPL (0.39) | LPLLIPGCXCR2SLC6A4SLC6A2 | |
| SCHEMBL13202078 | 0.80 | LPL (0.43) | LPLLIPGCXCR2ANPEPLAP3 | |
| SCHEMBL3319492 | 0.80 | CXCR2 (0.41) | LPLLIPGCXCR2 | |
| SCHEMBL19817457 | 0.80 | CXCR2 (0.41) | LPLLIPGCXCR2ALDH1A1 | |
| SCHEMBL20504832 | 0.79 | SLC6A2 (0.34) | LPLLIPGLTA4HCXCR2SLC6A4 | |
| SCHEMBL2586990 | 0.79 | LPL (0.42) | LPLLIPGCXCR2ANPEPLAP3 | |
| SCHEMBL30737822 | 0.79 | LPL (0.42) | LPLLIPGCXCR2ANPEPLAP3 | |
| SCHEMBL30393353 | 0.79 | LPL (0.42) | LPLLIPGCXCR2ANPEPLAP3 | |
| SCHEMBL11963741 | 0.79 | LPL (0.42) | LPLLIPGCXCR2ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697994-B | Fused quinazoline derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2022251497-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022197862-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | LPL 4880/4885LIPG 3777/4885LTA4H 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.